Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia

Objective: This study was conducted to determine the prevalence and severity of menopausal symptoms and their associated risk factors among postmenopausal breast cancer patients receiving adjuvant endocrine therapy. Methods: Postmenopausal breast cancer patients on endocrine therapy were recruited a...

Full description

Saved in:
Bibliographic Details
Published in:Climacteric : the journal of the International Menopause Society 2019-04, Vol.22 (2), p.175-181
Main Authors: Choo, S. B., Saifulbahri, A., Zullkifli, S. N., Fadzil, M. L., Redzuan, A. Md, Abdullah, N., Bustamam, R. S. Ahmad, Ahmad, H. Z., Shah, N. Mohamed
Format: Article
Language:English
Subjects:
Adjuvant endocrine therapy
Aged
Antineoplastic Agents, Hormonal - adverse effects
Aromatase Inhibitors - adverse effects
Breast cancer
Breast Neoplasms - drug therapy
Chemotherapy, Adjuvant - adverse effects
Cross-Sectional Studies
Endocrine therapy
Fatigue - epidemiology
Female
Health risk assessment
Hot Flashes - chemically induced
Hot Flashes - epidemiology
Humans
Malaysia
Malaysia - epidemiology
Mental Fatigue - epidemiology
Middle Aged
Musculoskeletal Pain - epidemiology
Pain
postmenopausal
Postmenopause - drug effects
Tamoxifen - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: This study was conducted to determine the prevalence and severity of menopausal symptoms and their associated risk factors among postmenopausal breast cancer patients receiving adjuvant endocrine therapy. Methods: Postmenopausal breast cancer patients on endocrine therapy were recruited at three hospitals in Malaysia. Presence and severity of menopausal symptoms were determined using the Menopause Rating Scale. Sociodemographic and clinical data were collected from medical records. Results: A total of 192 patients participated in this study. Commonly reported symptoms were musculoskeletal pain (59.9%), physical and mental exhaustion (59.4%), and hot flushes (41.1%). Multivariate analyses indicated that increasing number of years after menopause until the start of endocrine therapy was significantly associated with less likelihood of reporting menopausal symptoms and musculoskeletal pain. Patients with primary or secondary education levels reported significantly less menopausal urogenital symptoms compared to patients with a tertiary education level. Patients using aromatase inhibitors were twice as likely to experience musculoskeletal pain compared to patients using tamoxifen (odds ratio, 2.18; 95% confidence interval, 1.06-4.50; p 
ISSN:1369-7137
1473-0804
DOI:10.1080/13697137.2018.1540563